OSPHOS® is supplied as 15 mL (900 mg) of clodronate disodium (60 mg/mL) per vial and is ready-to-use (no reconstitution or dilution required).
In field studies, the most common side effects reported were signs of
discomfort or nervousness, cramping, pawing and/or colic within 2 hours
post-treatment (9% of horses treated: n=10). Eight out of ten of these
horses had resolution of their clinical signs purusant to 10 to 15 minutes of hand-walking. In one horse, clinical signs resolved without hand-walking. Only one experienced colic requiring treatment. That horse also developed hives and recovered after treatment consisting of a combination of flunixin and dexamethasone.
|
|
OSPHOS® is an injectable bisphosphonate solution for the control of clinical signs associated with navicular syndrome in horses four years of age and older. OSPHOS® inhibits bone resorption by binding to calcium phosphate crystals (inhibiting their formation and dissolution) and by exerting direct cellular effects on osteoclasts.
Tildren® (tiludronate) is a product which implements a similar mode-of-action. Tildren, however, requires a 90-minute intravenous infusion protocol for administration.
Dechra's OSPHOS® has the unique advantage of intramuscular injection and is a ready-to-use solution that does not require mixing or reconstitution.
In clinical trials evaluating 86 horses, clinical improvement is most
evident at 2 months post-treatment with 74.7% of the horses experiencing
improvement in their lameness score. For horses that initially respond to
OSPHOS®, it may be readministered at 3- to 6-month intervals based on
recurrence of clinical signs. The improvement seen in lameness scores
during the OSPHOS® field trial was achieved in the absence of concurrent corrective shoeing, pain medication or NSAIDs.
Please visit Dechra's client-friendly website for more information.
|